Keeping pressure on Amgen, Mirati draws mixed reviews on latest cut of KRAS data
As the close runner-up to Amgen’s Lumakras in the KRAS race, any data cut from Mirati’s adagrasib continues to draw scrutiny from analysts. And the latest batch of numbers from ASCO is a decidedly mixed bag.
While a quick comparison suggests that adagrasib spurred slightly more responses and led to a longer overall survival than Lumakras among a group of non-small cell lung cancer patients, its duration of response appears shorter and the safety profile continues to spark concern.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.